MedTrace Logo

Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation

NCT05378698 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-02-06

No results posted yet for this study

Summary

The clinical efficacy of tralokinumab has been demonstrated in the treatment of AD; its MOA however remains insufficiently understood. A better understanding of the mechanisms underlying the clinical effects of tralokinumab would be of great clinical benefit since it may ultimately help us to identify more precisely candidate patients who may benefit from a therapy with tralokinumab.

Conditions

Interventions

DRUG

Application of Tralokinumab

2 Arms 20 patients 5 healthy controls

Sponsors & Collaborators

  • Hochgebirgsklinik Davos-Wolfgang

    collaborator UNKNOWN

  • University of Zurich

    lead OTHER

Principal Investigators

  • Peter Schmid-Grendelmeier, Prof, MD · University of Zurich

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2025-03-04
Completion
2025-03-04

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05378698 on ClinicalTrials.gov